From Fringe to Funded: How Psychedelic Research Got Resourced
In 2010, the entire annual budget for psychedelic research worldwide could have fit in a mid-size philanthropy's discretionary grants. Today, the combined annual spending on psilocybin and related compounds from nonprofits, biotech companies, university endowments, and government sources runs into hundreds of millions of dollars. The shift happened fast, and understanding who is funding what — and what their incentives are — is essential context for anyone following this field.
The Nonprofit Foundations: Heffter, Usona, and MAPS
Three nonprofit organizations have played an outsized role in establishing psychedelic science as a credible academic field.
The Heffter Research Institute, founded in 1993 by chemist Dave Nichols and others, was the first to fund modern clinical trials with psilocybin. Heffter provided the early-stage grants that allowed Roland Griffiths at Johns Hopkins and Charles Grob at UCLA to run their initial studies — work that produced the data showing psilocybin's safety profile and potential in healthy volunteers and cancer patients, respectively. Without Heffter's patient capital in an era when no other funder would touch this research, the modern psychedelic renaissance would have started much later, or not at all.
Heffter remains focused narrowly on scientific research — it does not advocate for policy change, and it does not fund commercial operations. Its funding comes from private donors who have been willing to support high-risk, high-stigma science. The institute has moved more conservatively than the broader field's enthusiasm might suggest, which reflects the scientific rigor it has tried to maintain.
Usona Institute, founded in 2014, operates as a nonprofit medical research organization explicitly focused on psilocybin for major depressive disorder. Usona has run Phase 2 clinical trials with synthetic psilocybin (its compound is called PSIL201) and has a pathway toward potential FDA approval that parallels COMPASS Pathways but without the commercial profit motive. Usona's model is "open science" — it intends to make its data and, if approved, its compound available in a way that doesn't create a privately controlled monopoly on psilocybin therapy.
This distinction from commercial biotech is significant. Usona's funding comes primarily from the Riverstyx Foundation, which was established specifically to support this mission. The organization's nonprofit structure means that FDA approval, if it comes, would result in psilocybin being available as a generic compound rather than a patent-protected pharmaceutical.
MAPS (Multidisciplinary Association for Psychedelic Studies), founded by Rick Doblin in 1986, has been the most visible — and arguably most controversial — player in the space. MAPS has focused primarily on MDMA-assisted therapy for PTSD, not psilocybin, but its advocacy work, fundraising model, and public communications have shaped the entire field's trajectory.
MAPS's Phase 3 trials for MDMA-assisted therapy were funded through a massive charitable fundraising effort, raising over $130 million from thousands of donors. The FDA rejected MDMA-assisted therapy for PTSD in August 2024, a significant setback that sent reverberations through the psychedelic research world and prompted scrutiny of MAPS's clinical trial methodology and data integrity. As of 2026, MAPS is restructuring its clinical program to address the FDA's concerns. The MAPS story is a cautionary tale about the distance between promising Phase 2 data and regulatory approval.
Academic Centers: The University Research Ecosystem
Philanthropy has endowed several university-based research centers that now form the scientific backbone of the field.
Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) launched in 2019 with $17 million in funding from private donors including Tim Ferriss, who organized a group of Silicon Valley philanthropists to make the gift. The center, led by Matthew Johnson and previously by Roland Griffiths (who died in 2023), has published the most-cited psilocybin research in the world, covering depression, addiction, smoking cessation, and existential distress. The center continues to receive philanthropic funding and has expanded into federal grant territory.
Imperial College London's Centre for Psychedelic Research, founded by Robin Carhart-Harris (now at UCSF), was funded through a combination of UK charitable sources and crowdfunding. It produced highly influential neuroimaging research showing how psilocybin alters brain network connectivity and was home to the first published randomized controlled trial comparing psilocybin to escitalopram (Lexapro) for depression.
NYU Langone's Psychedelic Medicine Program, UC Berkeley's Center for the Science of Psychedelics, and programs at UC San Francisco, Stanford, and the University of Wisconsin-Madison represent a growing institutional footprint. Many of these centers now actively seek NIH funding, which was largely unavailable for psychedelic research until very recently.
Government Funding: A Shifting Landscape
The National Institutes of Health (NIH) awarded its first grants specifically for psilocybin research in 2022 and 2023, a milestone that would have been unimaginable a decade earlier. These grants have been relatively modest in size but represent a significant symbolic and practical shift — NIH funding brings with it institutional credibility, overhead support, and access to the broader academic research infrastructure.
The Department of Veterans Affairs (VA) launched a psychedelic therapy research program in 2023, with initial studies examining both MDMA and psilocybin for PTSD and depression in veterans. The VA studies are significant because the veteran population represents one of the clearest unmet medical needs in mental health and because VA research can proceed with fewer commercial incentives than private biotech.
President Trump's April 2026 executive order directing federal agencies to accelerate psychedelic research for veterans represents the most significant federal executive action in this space to date. The order directs the VA and DoD to expand research programs and reduce bureaucratic barriers to clinical trials. How this translates into actual funding and regulatory changes will become clearer over the next 12–18 months.
State-level funding is also emerging. Oregon allocated a portion of Measure 109 licensing fees to research, and Colorado's Proposition 122 created a natural medicine advisory board with research functions. These are small-scale but symbolically important investments.
Commercial Biotech: COMPASS Pathways and the Patent Landscape
COMPASS Pathways is a UK-based for-profit company that holds patents on specific formulations and delivery methods of synthetic psilocybin (COMP360). Its Phase 2b trial results, published in 2022, showed significant antidepressant effects at the 25mg dose in treatment-resistant depression. The company has announced Phase 3 trials and is pursuing FDA Breakthrough Therapy designation, which it received in 2018.
COMPASS is the most capitalized commercial player in psilocybin, having raised hundreds of millions of dollars from venture capital and public markets. It has attracted controversy for its patent strategy — seeking intellectual property protection not just on its specific formulations but on aspects of the psychedelic therapy session itself, drawing criticism from researchers and advocates who argue this would create barriers to access if the compound is approved.
Other commercial biotech companies active in psilocybin include Mydecine Innovations, Beckley Psytech, Field Trip Health (which pivoted and restructured), and several others. Most remain pre-revenue and dependent on continued capital raises.
The venture capital money in psychedelics — estimated at over $500 million cumulatively invested through 2025 — carries expectations of returns that nonprofit organizations do not. This shapes what gets studied (patentable compounds and delivery methods over natural mushrooms), what populations get prioritized (those with clear diagnostic categories and insurance reimbursement potential), and what timelines look achievable.
Philanthropic Networks: The People Behind the Money
Much of the nonprofit and academic funding traces back to a relatively small network of high-net-worth donors and family foundations, many with roots in technology and finance:
- The Tim Ferriss group that funded Johns Hopkins' center
- The Riverstyx Foundation behind Usona
- Steven and Alexandra Cohen Foundation (MDMA research)
- Carey and Claudia Turnbull (various academic programs)
- The Saisei Foundation and others funding specific research programs
This concentration has advantages — it enabled rapid scaling of research when the field was stigmatized and could not access conventional funding. It also raises questions about donor influence on research priorities, the selection of what conditions to study, and the terms under which results are made public.
What the Funding Landscape Means for Access
Funding shapes the research agenda, and the research agenda shapes what eventually becomes available to people. The dominance of biotech money incentivizes drug approval pathways that are expensive to navigate and result in regulated pharmaceutical products — potentially priced accordingly. The nonprofit path (Usona's model) explicitly aims at different outcomes: public domain data and generic availability.
These are not academic distinctions. If psilocybin-assisted therapy reaches mainstream healthcare, whether it costs $1,000 per session or $20,000 will depend in significant part on decisions being made right now about patents, funding structures, and regulatory strategy. Advocates who care about equity in access are watching these decisions carefully.